A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies

A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies
Condition:   Advanced Pancreatic Cancer
Interventions:   Drug: AB680;   Drug: Zimberelimab;   Drug: Nab-paclitaxel;   Drug: Gemcitabine
Sponsor:   Arcus Biosciences, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 1, 2022Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments